Current progress in lipid therapy

British Journal of Cardiology

Volumn 10, Issue 1, 2003, Pages 59-68

  Minhas, Rubin ^a  

^a Medway PCT   (United Kingdom)

Author keywords

Cholesterol; Cholesterol absorption inhibitors; Coronary heart disease; Ezetimibe; Fibrates; Rosuvastatin; Stains

Indexed keywords

ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; CHOLESTEROL ABSORPTION INHIBITOR; CREATINE KINASE; CYCLOSPORIN DERIVATIVE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; MACROLIDE; NICOTINIC ACID; PERMEASE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; CANCER; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; GENERAL PRACTICE; HEADACHE; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPERTENSION; INTESTINE CELL; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIN; PHARYNGITIS; PLEIOTROPY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY HEALTH CARE; PROTEIN BLOOD LEVEL; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0038070252     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Britton A, McPherson K. Monitoring the progress of the 2010 target for coronary heart disease mortality. National Heart Forum (2000).
2. Keys A. Seven Countries. A Multivariate Analysis of Death and Coronary Heart Disease. Cambridge, Massachusetts: Harvard University Press, 1980.
3. Martin MJ, Hully SB, Browner WS et al. (MRFIT) Multiple Risk Factor Intervention Trial. Serum cholesterol, blood pressure and mortality: Implications from cohort of 361,662 men. Lancet 19i86;ii:933-6.
4. Shaper AG, Pocock SJ, Walker M et al. Risk factors for ischaemic heart disease: The prospective phases of the British Regional Heart Study. J Epidemiol Community Health 1985;39:197-209.
5. Anderson KM, Castelli WP. Cholesterol and mortality: 30 years of follow up from the Framingham study. JAMA 1987;257;2176-80.
6. Assmann G, Schulte H, Oberwittler W, Hauss WH. New aspects in the prediction of coronary artery disease: The Prospective Cardiovascular Munster study. In: Fidge NH, Nestel PJ (eds). Proceedings of the 7th International Atherosclerosis Symposium. Amsterdam: Elsevier, 1986.
7. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-07.
8. Steinberg D, Parthaswarthy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol reduction: Modifications of LDL that increase its atherogenicity. N Engl J Med 1989;320:915-92.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease. Scandinavian Simvastatin Survival Study (4S). Lancet 1994;334:1383-9.
10. Sacks FM, Pfeffer MA, Moye LA et al. for the Cholesterol and Recurrent Events Trial Investigators. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N Engl J Med 1996;335:1001-09.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: A randomised controlled trial. Lancet 2002;360:(9236):7-22.
12. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30.
13. Wood D, Durrington P, Poulter N et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):1-29.
14. Department of Health. National Service Framework for Coronary Heart Disease. London: Department of Health, 2000.
15. National Institute for Clinical Excellence. Guidelines on the management of patients with type 2 diabetes. www.nice.org.uk (accessed 21.11.02).
16. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of the AFCAPS/TexCAPS, Airforce/Texas Coronary Atherosclerosis Prevention Study. JAMA 1988;279:1615-22.
17. Haq IU, Wallis EJ, Yeo WW, Jackson PR, Ramsay LE. Coronary events with lipid-lowering therapy: The AFCAPS/TexCAPS Trial: Letter to the editor. JAMA 1999;281(5);414.
18. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
19. Brady AJB, Oliver MA, Pittard JB. Secondary prevention in 24 431 patients with coronary heart disease: Survey in primary care. BMJ 2001;322:146.
20. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolaemia (the CURVES study). Am J Cardiol 1998;81(5):582-7.
21. Kastelein JP, Stein ES, Davidson MA et al. Simvastatin increases HDL-C and apolipoprotein A-1 levels significantly more than atorvastatin. J Am Coll Cardiol 2000;35(2)(suppl A):1009-173.
22. Olsson AG, Pears J, McKellar J et al. Effect of rosuvastatin on low density lipoprotein cholesterol in patients with hypercholesterolaemia. Am J Cardiol 2001;88:504.8.
23. Davidson M, Ma P, Stein EA et al. Comparison of effects on low density lipoprotein cholesterol and high density lipoprotein cholesterol with rosuvastatin versus atorvastatin with type IIa or IIb hypercholesterolaemia. Am J Cardiol 2002;89:268-75.
24. Waters D, Schwartz GG, Olsson AG. The Myocardial Ischemic Reduction with Aggressive Cholesterol Lowering (MIRACL) trial: A new frontier for statins? Curr Control Trials Cardiovasc Med 2001;2:111-14.
25. Rosenson R, Tangney C. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1996; 279(20):1643-50.
26. Archbold RA, Timmis AD. Cholesterol lowering and coronary disease: Mechanisms of risk reduction. Heart 1998;80:543-7.
27. Furberg C. Natural statins and stroke risk. Circulation 1999;99:185-8.
28. Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short term effects of atorvastatin on C-reactive protein. Eur Heart J 2002;23:794-9.
29. Eckel R, Plenge JK, Hernandez TL et al. Simvastatin lowers c-reactive protein within 14 days. Circulation 2002;106:1447-52.
30. Bellingham C. Cerivastatin withdrawal: The impacts. Pharmaceut J 2001;267:7161:222.
31. Shepherd J, Hunninghake D, Harris S et al. A review of the safety profile of rosuvastatin in an international phase II/III clinical trial programme. Int J Clin Pract 2002;(suppl 124):15.
32. Newman TB, Hulley SB. Carcinogenecity of lipid lowering drugs. JAMA 1996;275:55.
33. Bjerre LM, Lelorier J. Do statins cause cancer? A meta-analysis of large randomised clinical trials. Am J Med 2001;110:716.
34. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
35. Rubins HB, Robins SJ, Collins D et al. The VAHIT trial. N Engl J Med 1999;341:410-18.
36. Ling WH, Jones PJH. 1995 minireview of dietary phytosterol: A review of metabolism, benefits and side effects. Life Sci 1995;57:195-206.
37. Pollak OJ, Kritchevesky D. Sitosterol. In: Clarkson TB, Kritchevesky D, and Pollak OJ. (eds). Monographs on Atherosclerosis. Vol 10. New York: Karger S, 1981: 139-57.
38. Hernandez M, Montenegro J, Steiner M et al. Intestinal absorption of cholesterol is mediated by a saturable inhibitible transporter. Biochem Biophys Acta 2000;1486:232-42.
39. Bays HE, Moore PB, Drehobl MA et al. for the Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolaemia: Pooled analysis of two phase II studies. Clin Ther 2001;23:1209-30.
40. Knopp RH, Gitter H, Truitt H et al. Ezetimibe reduces low density lipoprotein cholesterol: Results of a phase III, randomised, double-blind, placebo-controlled trial. Atherosclerosis 2001;2(suppl 2):38 (abstract).
41. Melani L, Mills R, Hassman D et al. for the Ezetimibe Study Group. Ezetimibe coadministered with pravastatin in 538 patients with primary hypercholesterolaemia. World Congress of Cardiology. Sydney, Australia. 9 May 2002.
42. Davidson M, McGarry T, Bettis R et al. for the Ezetimibe Study Group. Ezetimibe coadministered with simvastatin in 668 patients with primary hypercholesterolaemia. 51st Annual Scientific Sessions of the American College of Cardiology, Atlanta, USA, 18 March 2002.
43. Ballantyne C, Houri J, Notarbartolo A et al. for the Ezetimibe Study Group. Ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolaemia. 51st Annual Scientific Sessions of the American College of Cardiology, Atlanta, USA, 18 March 2002.
44. Gagne C, Gaudet D, Bruckert E et al. for the Ezetimibe Study Group. Ezetimibe significantly reduces low-density lipoprotein cholesterol in homozygous familial hypercholesterolaemia. World Congress of Cardiology, Sydney, Australia. 9 May 2002.
45. Miettinen TA, Gylling H, Strandberg T, Sarna S. for the Finnish 4S Investigators. Baseline serum cholesterol as a predictor of recurrent coronary events in a subgroup of the Scandinavian Simvastatin Survival Study. BMJ 1998;316:1127-30.